Abstract:The gut-liver axis covers the bidirectional communication between the gut and the liver, and thus includes signals from liver-to-gut (e.g., bile acids, immunoglobulins) and from gut-to-liver (e.g., nutrients, microbiota-derived products, and recirculating bile acids). In a healthy individual, liver homeostasis is tightly controlled by the mostly tolerogenic liver resident macrophages, the Kupffer cells, capturing the gut-derived antigens from the blood circulation. However, disturbances of the gut-liver axis have been associated to the progression of varying chronic liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and primary sclerosing cholangitis. Notably, changes of the gut microbiome, or intestinal dysbiosis, combined with increased intestinal permeability, leads to the translocation of gut-derived bacteria or their metabolites into the portal vein. In the context of concomitant or subsequent liver inflammation, the liver is then infiltrated by responsive immune cells (e.g., monocytes, neutrophils, lymphoid, or dendritic cells), and microbiota-derived products may provoke or exacerbate innate immune responses, hence perpetuating liver inflammation and fibrosis, and potentiating the risks of developing cirrhosis. Similarly, food derived antigens, bile acids, danger-, and pathogen-associated molecular patterns are able to reshape the liver immune microenvironment. Immune cell intracellular signaling components, such as inflammasome activation, toll-like receptor or nucleotide-binding oligomerization domain-like receptors signaling, are potent targets of interest for the modulation of the immune response. This review describes the current understanding of the cellular landscape and molecular pathways involved in the gut-liver axis and implicated in chronic liver disease progression. We also provide an overview of innovative therapeutic approaches and current clinical trials aiming at targeting the gut-liver axis for the treatment of patients with chronic liver and/or intestinal diseases.

Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites

The Gut Microbiome and Intestinal Failure-Associated Liver Disease

The causal relationship between gut microbiota and end-stage liver disease: a bidirectional Mendelian randomization analysis

Role of Intestinal Microbes in Chronic Liver Diseases

Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study

Infectious Microecology in Liver Disease

Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer

The Gut Microbiota: How Does It Influence the Development and Progression of Liver Diseases

Relationship between Intestinal Dysregulation and Liver Disease

Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases

Gut Microbiome, Liver Immunology, and Liver Diseases

The Role of Gut Microbiota in Some Liver Diseases: From an Immunological Perspective

Gut Microbiota’s Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics

Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases

Role of the Intestinal Microbiome in Liver Fibrosis Development and New Treatment Strategies

Progress on liver dysfunction and small intestinal diseases

Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory

Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota.

The gut–liver axis and gut microbiota in health and liver disease

Gut Microbiota in Gastrointestinal Diseases: Insights and Therapeutic Strategies

Role of bile acids in liver diseases mediated by the gut microbiome